Gains market share and label expansion it is time to look ahead. Or actually go back to the ASH paper from 2011 to read about the Sgn33A preclinical data that Clay just called " some of the best he has EVER seen". It really is, and in AML where there is unmet need since it usually develops later in life and many can not tolerate the systemic toxicity. Preclinically it was compared with gemtuzumab Oz which gained approval as pfizers mylotarg, since withdrawn due to high incidences of hepatic toxicity.
Due to the highly potent pbd payload (1000x more potent than Adcetris payload) it was tested with very small doses and blew mylotarg away against all strains of AML especially the multi drug resistant ones.
Phase 1 enrolling and since this disease is so bad, if clinically it works, the approval process will be accelerated. Just looking ahead to our next exciting product.
I know that quite a few of us here that have been around a few years also had a stake in Micromet and were very encouraged by that data as well. Unfortunately MITI sold out and only Amgen will reap the profits. I doubled my money but still feel that mgmt sold out way too early. SGEN is different, They don't lack the confidence and experience to get it done on their own.
I just sold a tiny bit of my SGEN holdings, reluctantly I might add, to fund my next sub $10 biotech purchase. I have a simple strategy. Let the Baker Bros do all the research, follow their buys and narrow the list down to one based on my own preference. Yesterday's plunge in HALO was too interesting to pass up.
Back to the point, MITI 's ab was good, too bad we didn't get to see it all the way through.